News and Trends 7 Oct 2017 Mind the Gut: Copenhagen Exhibition Explores Bacteria and Feelings The exhibition Mind the Gut at the Medical Museion in Copenhagen opens its doors to visitors to challenge the view of our own bodies. The Medical Museion in Copenhagen has expanded its exhibition area to make way for Mind the Gut, an exploration of the complex relationship between our brain and bowels through art, science, […] October 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2017 Study Reveals No Evidence to Support Most European Cancer Drug Approvals A new study concludes the majority of cancer drugs approved by the EMA between 2009 and 2013 weren’t backed by sufficient evidence that they are effective. A team of researchers from King’s College London and the London School of Economics has published a new study reviewing the clinical data used to back the approval of […] October 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2017 British-Finnish Alliance to Bring Gene Therapy to the Masses FIT Biotech and Avacta hope to combine their technologies to produce highly specific, best-in-class gene therapy treatments. The two companies have spotted an opportunity to bring together their technologies and form a leading gene therapy system in a market that could be worth over $4.3B (€3.7B) by 2024. FIT Biotech, based in Finland, has been working on […] October 6, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 Spanish Biotech’s Stock Surges After Decision to Move out of Barcelona Oryzon Genomics announced it will move its headquarters from Barcelona to Madrid days after the Catalonian independence vote, making its stock grow by 30%. Oryzon Genomics, a Spanish biotech leveraging epigenetics to treat cancer, announced on Tuesday its decision to move out of Barcelona and establish its new headquarters in Madrid, citing the “optimization of […] October 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology Angle will raise £12.2M, which will allow it to acquire assets from Axela to put the finishing touches to its full liquid biopsies solution. Angle is a leader in the liquid biopsy market, the ‘holy grail’ of cancer diagnostics. The company has developed technology that recently outperformed the gold standard in the field. Angle is hoping to raise £12.2M […] October 5, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 Dutch Clinical Trial Points to Fecal Transplant as Diabetes Treatment A small clinical trial in the Netherlands has found that a fecal transplant from a lean donor can temporarily improve diabetes symptoms in obese men. Research published in Cell Metabolism from the University of Amsterdam has found that a fecal transplant from lean men to obese men can cause a short-term improvement in insulin resistance. This […] October 5, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 British Biotech Founder Receives the Nobel Prize in Chemistry 2017 Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This year’s Nobel Prize in Chemistry has been awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy. This technology, now widely used in structural biology labs, is considered a stepping […] October 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 Synbio adds Softness: Robots of the Future will be Squishy As AI and machine learning approach biotech, synthetic biology is approaching soft robotics. What is it bringing to the field? Conventional rigid-bodied robots are used to perform specific single tasks efficiently but often with limited adaptability when it comes to interacting with humans. During the past few years, soft robots made of highly pliable materials […] October 5, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Ablynx Launches $175M IPO on Wall Street After Phase III Success Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […] October 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […] October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Oral Drug to Treat Uterine Fibroids Boasts Phase III Success Myovant’s partner Takeda has reported Phase III results showing relugolix to be more effective in treating uterine fibroids than existing hormonal therapy. Myovant has announced positive results from its lead candidate, relugolix, which showed itself to be better than leuprorelin injections — a common first-line treatment — at reducing menstrual bleeding in a Phase III trial in patients […] October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 4 Oct 2017 4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […] October 4, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email